UnitedHealth Group Incorporated Q2 FY2026 earnings call

- Enterprise Strategic Priorities - Management is focused on improving consumer and provider experiences by addressing core system weaknesses: prior authorization complexity, information accuracy, access and scheduling, digital service delivery, and care navigation. - Artificial intelligence is a core enterprise priority, embedded across all operations to reduce administrative burden, improve decision-making, and accelerate modernization; management views AI as the future operating infrastructure that will drive compounding efficiency gains over time. - The company maintains a long-term target of 13-16% annual earnings growth, and management reaffirmed confidence in this target after 2026 outperformance.

- UnitedHealthcare Operational Progress - Committed to eliminating 30% of prior authorization volume and nearly two-thirds of pediatric prior authorization requirements by the end of 2026, with a goal of processing 80% of prior authorizations in real time by the end of 2027. - AI is being deployed across all provider and consumer interactions to automate complex claims, enable real-time data sharing, and customize utilization management, reducing administrative work for both providers and the plan while improving satisfaction.

- Optum Operational Progress - OptumHealth has improved care outcomes: transitions of care initiatives delivered a 10% reduction in hospitalizations; home health pilot programs reduced readmissions and cut skilled nursing facility stays; rural home-based care programs now reach nearly 90% of U.S. counties with 2.5 million annual patient visits, to be expanded by end of 2026. - 70% of employed OptumHealth providers already use AI ambient listening documentation, on track to exceed 90% by end of 2026, reducing clinician burnout by 90% and freeing up time for patient care; patient experience is up 5% YoY, and patient access has expanded by 200,000 additional patient-facing hours. - OptumInsight is commercializing internal AI use cases into external products: the AI-powered digital prior authorization product launched earlier this year has already processed 500,000 prior authorizations for external clients, saving 69,000 administrative hours to date.

UnitedHealth Group (parent): Total Q2 2026 revenues were $112 billion, flat year-over-year; adjusted operating earnings grew 55% YoY to $8 billion; adjusted earnings per share was $6.38, up from $4.00 YoY.

UnitedHealthcare (benefits segment): - Medicare Advantage: Performance exceeded expectations, with medical cost trends coming in below the initial 10% forecast due to targeted benefit design, network curation, and a milder respiratory season; full-year 2026 margins are expected to finish above 3%, enrollment is projected to decline by ~1.1 million members. - Medicaid: Overall performance and cost trends were in line with expectations; 2026 full-year margins are expected to remain pressured, within the previously guided range of -1% to -1.7%, as reimbursement rates continue to lag underlying medical cost trends; early improvements are seen in efforts to address elevated behavioral health costs. - Commercial: Medical cost trends are modestly above the prior 11% forecast, driven by the ineffective Independent Dispute Resolution (IDR) process under the No Surprises Act, more aggressive provider coding and billing intensity, and rising specialty pharmacy costs (including GLP-1s); margin recovery is delayed past the original 2027 target, with no full margin expansion expected in 2026.

Optum (services and care segment): - OptumHealth: Momentum is building as the business refocuses on its integrated value-based care model; first half 2026 performance was slightly above plan, with value-based care margins modestly exceeding expectations, driven by improved care management and tighter operating discipline; full-year 2026 operating earnings guidance is raised to at least $2.2 billion. - OptumRx: Performed in line with plan, with customer retention rates in the high 90% range; on track to reach 95% of clients on 100% manufacturer rebate pass-through by the end of 2026, ahead of the 2027 full target. - OptumInsight: Performed slightly above Q2 expectations, driven by early traction for AI-enabled products; remains on a multi-year reinvestment path, with full-year guidance unchanged as some client transaction volume shifted from H2 to H1 2026, and continued reinvestment in new AI products is planned for the back half.

- Full-year 2026 adjusted earnings per share guidance is raised to a range of $19.50 to $20.00, up from prior guidance. - Full-year 2026 UnitedHealthcare operating earnings guidance is raised to at least $12 billion, while OptumHealth operating earnings guidance is raised to at least $2.2 billion. - Full-year 2026 share repurchase guidance is doubled to at least $5 billion, up from the initial $2.5 billion target; the annualized dividend was increased to $9.28 per share. - The full-year 2026 medical care ratio is expected to be 88.1% ± 25 basis points, with the operating cost ratio expected to come in at the higher end of the prior range due to investments in AI, people, and community initiatives. - The company remains on track to reduce its debt-to-capital ratio to approximately 40% by the end of 2026, down from 41.2% at the end of Q2. - Earnings seasonality remains unchanged: ~75% of UnitedHealthcare earnings and nearly all of OptumHealth earnings are recognized in the first half of 2026, while ~55% of OptumRx and OptumInsight earnings are recognized in the second half. - Management reaffirmed the long-term 13-16% annual earnings growth target, stating the 2026 outperformance provides a durable baseline for future growth.

- Persistently elevated medical cost trends across all business segments, well above pre-pandemic historical levels, remain a core headwind. - Commercial business cost pressures are accelerating due to ongoing issues with the federal IDR process under the No Surprises Act: 40% of IDR claims are ineligible, 60% of disputes are concentrated with just five providers, and average arbitrator payouts to out-of-network providers are 11x Medicare rates (up to 30x in some cases), pushing incremental trend 50 basis points higher in 2026 and delaying commercial margin recovery past 2027. - Medicaid margins remain pressured because state reimbursement rate increases continue to lag rising medical costs, particularly for specialty pharmacy, home and community-based services, behavioral health, and inpatient skilled nursing facility costs for complex populations. - Medicare Advantage Star Ratings have become increasingly challenging in recent years, with 2026 industry scores at the lowest level in a decade, creating uncertainty around future ratings and related revenue. - While 2026 Medicare medical trends are currently below plan, trends still remain at elevated levels, and full year results are not yet final, leaving residual uncertainty around full year performance.

Q: Can you update Medicaid 2026 margin expectations and explain the magnitude of commercial cost pressure and the timeline for commercial margin recovery? A: Medicaid 2026 full-year margins will remain within the previously guided range of -1% to -1.7%, with Q2 performance meeting expectations. Cost trends remain elevated but stable, and 80% of 2026 annual revenue has already had rate adjustments that are within forecast, though rate increases continue to lag medical trend. For commercial, cost trends are modestly above the 11% prior forecast, with the flawed IDR process adding 50 basis points of incremental 2026 trend. Margin recovery that was originally targeted for 2027 will be delayed, though management remains confident it will eventually return to the historical 7%+ margin target over the multi-year journey.

Q: Where does the company's 1-year turnaround effort stand, and is the long-term 13-16% earnings growth target still achievable? A: Management will remain in a constant state of improvement and will never consider the turnaround complete, aligned with the company's mission to improve the broader health system. Management has never wavered from the 13-16% long-term growth target, and new AI-enabled productivity opportunities make this target more achievable than in the past.

Q: Why has IDR cost pressure accelerated now after being in place for years, and can this be incorporated into future pricing? A: IDR acceleration is driven by rapidly growing dispute volume, structural flaws in the process, and increasing concentration of disputes among a small number of providers. Up to 40% of IDR claims are ineligible, 60% of disputes come from just five entities, and average arbitrator payouts are now 11x Medicare rates, with some as high as 30x. The process is not working as Congress intended and requires legislative reform, though management continues to adjust pricing to reflect the ongoing pressure.

Q: Can AI initiatives drive upside to long-term margin targets, and what is the timeline for those gains? A: AI is a transformational, enterprise-wide initiative that is reimagining nearly all operations, with compounding efficiency benefits that will accelerate through 2027 and become more material from 2028 onward. AI improves administrative efficiency, automates complex processes like prior authorization, supports clinical decision-making, and reduces clinician burnout, with internal use cases already being commercialized as revenue-generating products for external clients through OptumInsight. Management emphasizes clinicians will always retain final decision-making for non-routine cases, and human support will always remain available for consumers.